You are here:

nivolumab (Opdivo) for cHL

Advice

following a full submission assessed under the end of life and ultra-orphan process:

nivolumab (Opdivo®) is accepted for use within NHS Scotland.

Indication under review: the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

In an open-label, single-arm study, a clinically meaningful objective response rate was achieved in patients with relapsed or refractory cHL treated with nivolumab.
SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of nivolumab and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: nivolumab (Opdivo) for cHL
SMC Drug ID: 1240/17
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 July 2017

Back